Passage Bio, Inc.
PASG
$7.35
-$0.29-3.80%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 13.20% | -3.81% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 19.47% | -16.25% | |||
| Operating Income | -19.47% | 16.25% | |||
| Income Before Tax | -67.54% | 17.43% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -67.54% | 17.43% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -67.54% | 17.43% | |||
| EBIT | -19.47% | 16.25% | |||
| EBITDA | -19.93% | 16.64% | |||
| EPS Basic | -67.49% | 17.69% | |||
| Normalized Basic EPS | -22.24% | 17.69% | |||
| EPS Diluted | -67.49% | 17.69% | |||
| Normalized Diluted EPS | -22.24% | 17.69% | |||
| Average Basic Shares Outstanding | 0.03% | 0.31% | |||
| Average Diluted Shares Outstanding | 0.03% | 0.31% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||